Tenelia Elderly CGMS Study(TEDDY)

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase IV Study to Evaluate the Efficacy and Safety of Tenelia® in Patients Aged 65 and Older With Inadequately Controlled Type 2 Diabetes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03508323

Enrollment

Registered

2018-04-25

Start date

2018-04-03

Completion date

2019-12-12

Last updated

2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

To assess the efficacy and safety of Teneligliptin in Patients aged 65 and Older with inadequately controlled type 2 diabetes.

Detailed description

To assess the efficacy and safety of Teneligliptin in Patients aged 65 and Older with inadequately controlled type 2 diabetes.

Interventions

DRUGTeneligliptin

20mg/qd

DRUGPlacebo

1T/qd

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are 65 years or older on screening * Patients with type 2 diabetes mellitus * Patients with 7.0% ≤ HbA1c ≤ 9.0% at the screening visit * Patients with FPG \< 270mg/dL on screening visit

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
HbA1c	after 12wks on baseline	Change of HbA1c

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026